Skip to main content

Genetic Counseling for Lysosomal Storage Diseases

  • Chapter
Lysosomal Storage Disorders
  • 1221 Accesses

In many ways, the role of the genetic counselor working with patients and families with a lysosomal storage disease is similar to a counselor in other pediatric and adult counseling situations. The goals of counseling; education, access to health care, and supportive counseling are the same. Although the goals of counseling are simply stated, an effective counseling session is always a complex interaction. It is an empathic exchange where the counselor promotes understanding of the particular disease, the inheritance pattern, takes a family history, provides recurrence risks, and reviews diagnostic testing, disease management issues, and supportive resources, while simultaneously learning about family structure, dynamics, and the impact of the diagnosis. The counselor assesses the level of understanding about the disease and the appropriate resources to assist the patient and family facing an inherited disease. A balance of teaching and counseling and the ability to be flexible and responsive to the counselee is key for achieving an effective interaction. The chapter is designed as a resource for counselors or other health care providers interested in an update on counseling issues for this group of treatable lysosomal storage diseases. Six genetic counselors who have been involved with the lysosomal storage disease community for the last decade draw on their counseling expertise to provide a disease summary and clinical counseling pearls for Gaucher disease, Fabry disease, Mucopolysaccharidosis (MPS) type 1, MPS II, MPS VI, and Pompe disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Amartino, H. Painceira, D. Pomponio, R.J. Niizawa, G. Sabio Paz, V. Blanco, M.A. Chamoles, N.A. (2006). Two clinical forms of glycogen-storage disease type II in two generations of the same family. Clin Genet 69:187-188.

    Article  CAS  PubMed  Google Scholar 

  • An, Y. Young, S.P. Kishnani, P.S. Millington, D.S. Amalfitano, A. Corzo, D. Chen, Y.T. (2005). Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85:247-254.

    Article  CAS  PubMed  Google Scholar 

  • Ausems, M.G. Verbiest, J. Hermans, M.P. Kroos, M.A. Beemer, F.A. Wokke, J.H. Sandkuijl, L.A. Reuser, A.J. van der Ploeg, A.T. (1999). Frequency of glycogen storage disease type II in The Netherlands: Implications for diagnosis and genetic counselling. Eur J Hum Genet 7:713-716.

    Article  CAS  PubMed  Google Scholar 

  • Barranger, J.A. Ginns, E.I. (1989) Glucosylceramide lipidosis: Gaucher disease. In: Scriver, C.R. Beaudet, A. Sly, W.S. Valle, D. (Eds). The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill; pp. 1677-1698.

    Google Scholar 

  • Barranger, J.A. O’Rourke, E. (2001). Lessons learned from the development of enzyme replacement therapy for Gaucher disease. J Inherit Metab Dis 24 Supp 2:87-96.

    Article  Google Scholar 

  • Bennett, R.L, Hart, K. O’Rourke, E, Barranger, J.A. Johnson, J, MacDermot, K.D. Pastores, G.M. Steiner R.D. Tadhani R. (2002). Fabry Disease in Genetic Counseling Practice: Recommendations of the National Society of genetic Counselors. J Genet Counsel. 11:121-146.

    Article  Google Scholar 

  • Brady, R.O. Grabowski, G.A. Thadhani, R. (2000). Fabry disease: α-galactosidase A deficiency. Gardiner-Caldwell SynderMed 1-8.

    Google Scholar 

  • Brady, R.O. Murray, G.J. Moore, D.F. Schiffmann, R. (2001). Enzyme replacement therapy in Fabry disease. J Inher Metab Dis 24 Supp 2:18-24.

    Article  CAS  PubMed  Google Scholar 

  • Case, L.E. Kishnani, P.S. (2006). Physical therapy management of Pompe disease. Genet Med 8:318-327.

    Article  PubMed  Google Scholar 

  • Charrow, J. Andersson, H.C. Kaplan, P. Kolodny, E.H. Pastores, G.M. et al. (2004). Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations. J Pediatr 144:112-120.

    Article  CAS  PubMed  Google Scholar 

  • Cox, T. Lachmann, R. Hollak, C. Aerts, J. van Weely, S. Hrebicek, M. Platt, F.M, Butters, T.D Dwek, R. Moyses, C. Gow, I. Elstein, D. Zimran, A. (2000). Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355:1481-1485.

    CAS  Google Scholar 

  • Damiano, A.M.Pastores, G.M. Ware, J.E. (1998) The health related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: Results from a retrospective study. Qual Life Res 7:373-86.

    Article  CAS  PubMed  Google Scholar 

  • Desnick, R.J. Brady, R.O. Barranger, J.A. Collins, A.J. Germain, D.P. Goldman, M. Grabowski, G.A. Packman, S. Wilcox, W.R. (2003). Fabry disease, an under-reco-gnized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338-346.

    PubMed  Google Scholar 

  • Elstein, D. Hollak, C.E. Aerts, J.M. vanWeely, S. Maas, M. Cox, T.M. Lachmann, R.H. Hrebicek, M. Platt, F.M. Butters, T.D. Dwek, R.A. Zimran, A. (2004). Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757-766.

    Article  CAS  PubMed  Google Scholar 

  • Eng, C.M. Guffon, N. Wilcox, W.R. Germain, D.P, Lee, P. Waldek, S. Caplan, L. Linthorst, G.E. Desnick, R.J. (2001). Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Eng J Med 345: 9-16.

    Article  CAS  Google Scholar 

  • Grabowski, G.A. Beutler, E. (2001). Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K (Eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; pp. 3635-3638.

    Google Scholar 

  • Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. (2005). Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 7: 143-146.

    Article  CAS  PubMed  Google Scholar 

  • Hagemans, M.L. Janssens, A.C. Winkel, L.P. Sieradzan, K.A. Reuser, A.J. Van Doorn, P.A. Van der Ploeg, A.T. (2004). Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63:1688-1692.

    CAS  PubMed  Google Scholar 

  • Hagemans, M.L. Winkel, L.P. Hop, W.C. Reuser, A.J. Van Doorn, P.A. Van der Ploeg, A.T. (2005). Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64:2139-2141.

    Article  CAS  PubMed  Google Scholar 

  • Harmatz, P. Ketteridge, J. Giugliani, R. Guffon, N. Teles, E. Miranda, S, Swiedler, S. Hopwood, J.J. (2005). Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681-e689.

    Article  PubMed  Google Scholar 

  • Harmatz, P. Whitley, C.B. Waber, L. Pais, R. Steiner, R. Plecko, B. Kaplan, P. Simon, J. Butensky, E. Hopwood, J.J. (2004). Enzyme replacement therapy in mucopoly-saccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144(5):574-580.

    Article  PubMed  CAS  Google Scholar 

  • Hermans, M.M. van Leenen, D. Kroos, M.A. Beesley, C.E. Van Der Ploeg, A.T. Sakuraba, H. Wevers, R. Kleijer, W. Michelakakis, H. Kirk, EP. Fletcher, J. Bosshard, N. Basel-Vanagaite, L. Besley, G. Reuser, A.J. (2004). Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23:47-56.

    Article  PubMed  CAS  Google Scholar 

  • Hoefsloot, L.H. van der Ploeg, A.T. Kroos, M.A. Hoogeveen-Westerveld, M. Oostra, B.A. Reuser, A.J. (1990). Adult and infantile glycogenosis type II in one family, explained by allelic diversity. Am J Hum Genet 46:45-52.

    CAS  PubMed  Google Scholar 

  • Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M. (2004). Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I, Mol Genet Metab 83:163-174.

    Article  CAS  PubMed  Google Scholar 

  • Kishnani, P. Corzo, D. Nicolino, M. Byrne, B. Mandel, H. Hwu, W.L. Leslie, N. Levine, J. Spencer, C. McDonald, M. Li J, DuMontier, J. Michael, H. Chien, Y.H. Hopkin, R. Vijayaraghavan, S. Gruskin, D. Bartholomew, D. van der Ploeg, A. Clancy, J.P. Parini, R. Morin, G. Beck, M. Delagastine, G. S. Jokic, M. Thurberg, B. Richards, S. Bali, D. Davison, M. Worden, M. Chen, Y.T. Wraith, J.E. (2007). Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109.

    Article  CAS  PubMed  Google Scholar 

  • Kishnani, P.S. Howell, R.R. (2004). Pompe disease in infants and children. J Pediatr 144:S35-43.

    Article  CAS  PubMed  Google Scholar 

  • Kishnani, P.S. Hwu, W.L. Mandel, H. Nicolino, M. Yong, F. Corzo, D. (2006). A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-676.

    Article  PubMed  Google Scholar 

  • Kishnani, P.S. Steiner, R.D. Bali, D. Berger, K. Byrne, B.J. Case, L.E. Crowley, J.F. Downs, S. Howell, R.R. Kravitz, R.M. Mackey, J. Marsden, D. Martins, A.M. Millington, D.S. Nicolino, M. O’Grady, G. Patterson, M.C. Rapoport, D.M. Slonim, A. Spencer, C.T. Tifft, C.J. Watson, M.S. (2006). Pompe disease diagnosis and management guideline. Genet Med 8:267-288.

    Article  PubMed  Google Scholar 

  • Li, Y. Scott, C.R. Chamoles, N.A. Ghavami, A. Pinto, B.M. Turecek, F. Gelb, M.H. (2004). Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785-1796.

    Article  PubMed  CAS  Google Scholar 

  • Litjens, T. Hopwood, J.J. (2001) Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 18:282-295.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

O'Rourke, E., Laney, D., Morgan, C., Mooney, K., Sullivan, J. (2007). Genetic Counseling for Lysosomal Storage Diseases. In: Lysosomal Storage Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-70909-3_13

Download citation

Publish with us

Policies and ethics